Description:
Interacts with DNA through DNA Topoisomerase II-mediated mechanisms.

Text:
REFERENCES 
(1) Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J. S. Doxorubicin 
Cardiomyopathy. Cardiology 2010, 115, 155162. (2) Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, 
F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA Topoisomerase 
IIMediated Interaction of Doxorubicin and Daunorubicin 
Congeners with DNA1. Can. Res. 1989, 49, 59695978. (3) Pommier, Y. Topoisomerase I Inhibitors Camptothecins and 
Beyond. Nat. Rev. Cancer 2006, 6, 789802. (4) Sim, S.P. ; Gatto, B.; Yu, C.; A. Liu, A.; Li, T.K. ; S. Pilch, D.; J. 
LaVoie, E.; F. Liu, L. Differential Poisoning of Topoisomerases by 
Menogaril and Nogalamycin Dictated by the Minor GrooveBinding 
Nogalose Sugar. Biochemistry 1997, 36, 1328513291.


---

Description:
An anticancer drug used in the treatment of various cancers including ovarian, multiple myeloma, and leukemia.

Text:
(5) Lomovskaya, N.; Otten, S. L.; DoiKatayama, Y.; Fonstein, L.; Liu, 
X. C.; Takatsu, T.; InventiSolari, A.; Filippini, S.; Torti, F.; Colombo, 
A. L.; Hutchinson, C. R. Doxorubicin Overproduction in 
Streptomyces Peucetius Cloning and Characterization of the DnrU 
Ketoreductase and DnrV Genes and the DoxA Cytochrome P450 
Hydroxylase Gene. J. Bacteriol. 1999, 181, 305318. (6) Doxorubicin Market By Application (Ovarian, Multiple Myeloma, 
Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, 
Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2018  
2024; 2016. (7) Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, 
F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA Topoisomerase 
IIMediated Interaction of Doxorubicin and Daunorubicin 
Congeners with DNA1. Can. Res. 1989, 49, 59695978. (8) Patel, A. G.; Kaufmann, S. H. How Does Doxorubicin Work?
